Answers are grounded in this paper and cite their sources.
BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) was administered to 6 children with central nervous system leukemia and 8 children with solid tumors. Being lipid soluble, BCNU has the capacity to cross the “blood-brain barrier,” making it a potentially effective agent for the parenteral treatment of CNS leukemia. Remission of CNS manifestations occurred in 3 of 6 children with CNS leukemia. Temporary regression of tumor was noted in 2 patients with Ewing's sarcoma and in one with neuroblastoma. Thrombocytopenia was a constant feature in all patients. Two died from hemorrhage associated with thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Iriarte et al. (1966) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: